REPL - レプリミュ―ン （Replimune Group Inc.） レプリミュ―ンREPLのチャート
REPLの企業情報
| symbol | REPL |
|---|---|
| 会社名 | Replimune Group Inc （レプリミュ―ン） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Replimune Group Inc. is a clinical-stage biotechnology company. The Company is engaged in the field of oncolytic immunotherapy to treat the cancer patients. The Company applies its Immulytic platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The Company is focused on developing a pipeline of oncolytic immunotherapy product candidates to provide clinical benefits to cancer patients. Its product candidates include RP RP2 and RP3. The Company is focused on Phase 1/2 clinical trial with its lead product candidate RP1 in approximately 150 patients with a range of solid tumors. レプリミュ―ンは米国のバイオ医薬品企業。臨床段階で、がん治療における腫瘍崩壊性免疫療法の開発に従事する。同社は独自の「Immulytic」プラットフォ―ムを使用して、固形腫瘍に対する患者の免疫システムを最大限に活性化させることを目的とする医薬品候補を開発する。本社所在地はマサチュ―セッツ州ウォ―バ―ン。 replimune group, inc., a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. it uses its proprietary immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. the company's lead product candidate is rp1, a selectively replicating version of herpes simplex virus 1, which is in phase i/ii clinical trials for a range of solid tumors; and that is in phase ii clinical trials for patients with cutaneous squamous cell carcinoma. it is also developing rp2, which is in phase i clinical trials for an anti-ctla-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by ctla-4; and rp3 to express immune-activating proteins that stimulate t cells. replimune group, inc. was founded in 2015 and is headquartered in woburn, massachusetts. |
| 本社所在地 | 18 Commerce Way Woburn MA 01801 USA |
| 代表者氏名 | ― |
| 代表者役職名 | ― |
| 電話番号 | +1 781-995-2443 |
| 設立年月日 | 42917 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2018年 |
| 従業員数 | 44人 |
| url | www.replimune.com |
| nasdaq_url | https://www.nasdaq.com/symbol/repl |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -21.81300 |
| 終値（lastsale） | 12.41 |
| 時価総額（marketcap） | 391581069.52 |
| 時価総額 | 時価総額（百万ドル） 366.33810 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 400.67010 |
| 当期純利益 | 当期純利益（百万ドル） -26.19400 |
| 決算概要 | 決算概要 BRIEF: For the three months ended 30 June 2018 Replimune Group Inc revenues was not reported. Net loss increased from $3.6M to $10M. Higher net loss reflects Other Non Operating I/E increase from $0K to $5.5M (expense) Research and development increase of 68% to $3.8M (expense) General and administrative increase from $861K to $1.8M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.12 to -$0.32. |
REPLのテクニカル分析
REPLのニュース
Director at Replimune Group Acquires Company Stock Options Worth 50,400 Shares 2023/06/05 15:00:28 Benzinga
Veleka PeeplesDyer , Director at Replimune Group (NASDAQ: REPL ), reported a large acquisition of company stock options on June 5, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Monday showed that PeeplesDyer, Director at Replimune Group, a company in the Health Care sector, was just awarded stock options worth 50,400 shares of REPL. The options give PeeplesDyer the right to buy the company''s stock at $18.48 per share. Replimune Group shares are trading up 13.43% at $21.54 at the time of this writing on Monday morning. Since the current price is $21.54, this makes PeeplesDyer''s 50,400 shares worth … Full story available on Benzinga.com
Replimune Appoints Veleka R. Peeples-Dyer to its Board 2023/06/05 12:06:06 Investing.com
https://www.investing.com/news/assorted/replimune-appoints-veleka-r-peeplesdyer-to-its-board-432SI-3098239
Replimune to Present at the Jefferies Global Healthcare Conference 2023/06/01 20:01:00 GlobeNewswire
WOBURN, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, today announced that members from the Replimune management team will present in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 8, 2023 at 1:00 PM ET at the Marriot Marquis in New York NY.
Replimune to Present at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting 2023/05/25 21:00:00 GlobeNewswire
WOBURN, Mass., May 25, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced multiple presentations at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, IL from June 2-6, 2023.
Recap: Replimune Group Q4 Earnings 2023/05/18 14:25:11 Benzinga
Replimune Group (NASDAQ: REPL ) reported its Q4 earnings results on Thursday, May 18, 2023 at 08:00 AM. Here''s what investors need to know about the announcement. Earnings Replimune Group missed estimated earnings by 7.25%, reporting an EPS of $-0.74 … Full story available on Benzinga.com
Replimune announces proposed public offering of up to $125M 2022/12/07 21:52:32 Seeking Alpha
Replimune (REPL) on Wednesday announced a proposed public offering of up to $125M of shares and pre-funded warrants. Read more on the offering here.
Replimune Group PT Raised to $34 at SVB Leerink 2022/12/07 20:26:02 Investing.com
https://www.investing.com/news/pro/replimune-group-pt-raised-to-34-at-svb-leerink-432SI-2959482
Why Prometheus Biosciences Shares Are Trading Higher By Over 184%? Here Are 55 Stocks Moving In Wednesday''s Mid-Day Session 2022/12/07 18:45:59 Benzinga
Gainers Prometheus Biosciences, Inc. (NASDAQ: RXDX ) shares jumped 184.2% to $102.49 after the company announced results for PRA023 in both ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a studies. ARTEMIS-UC met the primary endpoint. TransCode Therapeutics, Inc. (NASDAQ: RNAZ ) shares climbed 59.1% to $0.6679 after the company reported withdrawal of registration statement. BioVie Inc. (NASDAQ: BIVI ) gained 26.2% to $5.87. BioVie recently announced results from two Phase 2 trials assessing NE3107''s potential in Parkinson''s Disease (PD) and Alzheimer''s Disease (AD). Bit Brother Limited (NASDAQ: BTB ) climbed 23.1% to $0.4680. Vor Biopharma Inc. (NASDAQ: VOR ) climbed 21.4% to $5.22 after the company disclosed initial clinical data from VBP101, its Phase 1/2a multicenter, open-label, first-in-human study of tremtelectogene empogeditemcel or “trem-cel” (formerly VOR33) in patients with acute myeloid leukemia. Vor Bio also priced underwritten offering of 15.3 million shares of common stock at $4.30 per share.
Replimune Shares Surge After Early Data From Pretreated Melanoma Patients 2022/12/07 15:05:11 Benzinga
Replimune Group Inc (NASDAQ: REPL ) announced initial data from the first 75 patients from the anti-PD1 failed cutaneous melanoma cohort of the IGNYTE clinical evaluating RP1 (vusolimogene oderparepvec) combined with Bristol-Myers Squibb Co''s (NYSE: BMY ) Opdivo (nivolumab). The overall response rate (ORR) was 36%, and the complete response (CR) rate was 20% compared to the 12.5% shown in the prior 16 patients presented … Full story available on Benzinga.com
Replimune in pact with Roche to study cancer drug combos 2022/12/07 12:32:42 Seeking Alpha
Replimune Group (REPL) announced a collaboration with Roche (RHHBY) (RHHBF) on Wednesday to study combination therapies for cancer. Read the full story here.
Replimune Group, Inc. (NASDAQ:REPL) Shares Sold by Credit Suisse AG 2021/11/28 09:32:41 Dakota Financial News
Credit Suisse AG cut its holdings in Replimune Group, Inc. (NASDAQ:REPL) by 26.4% during the second quarter, HoldingsChannel reports. The fund owned 14,250 shares of the companys stock after selling 5,104 shares during the period. Credit Suisse AGs holdings in Replimune Group were worth $547,000 at the end of the most recent quarter. A number []
Replimune Group (NASDAQ:REPL) Earns Overweight Rating from Analysts at Piper Sandler 2021/11/22 08:38:41 Transcript Daily
Piper Sandler started coverage on shares of Replimune Group (NASDAQ:REPL) in a research note released on Friday morning, PriceTargets.com reports. The brokerage issued an overweight rating and a $52.00 price objective on the stock. REPL has been the subject of several other reports. HC Wainwright restated a buy rating and set a $59.00 target price []
Replimune Group, Inc. (NASDAQ:REPL) Director Fund Iv L.P. Omega Sells 2,441 Shares 2021/11/19 15:02:42 Transcript Daily
Replimune Group, Inc. (NASDAQ:REPL) Director Fund Iv L.P. Omega sold 2,441 shares of the firms stock in a transaction that occurred on Thursday, November 18th. The stock was sold at an average price of $33.50, for a total transaction of $81,773.50. The sale was disclosed in a filing with the SEC, which is accessible through []
Replimune Group (NASDAQ:REPL) Earns Buy Rating from HC Wainwright 2021/11/19 11:08:41 Dakota Financial News
HC Wainwright reissued their buy rating on shares of Replimune Group (NASDAQ:REPL) in a research note issued to investors on Monday morning, Analyst Ratings Network reports. They currently have a $59.00 target price on the stock. REPL has been the subject of several other research reports. SVB Leerink lowered their price target on Replimune Group []
Insider Selling: Replimune Group, Inc. (NASDAQ:REPL) Director Sells $127,984.01 in Stock 2021/11/13 11:50:41 Transcript Daily
Replimune Group, Inc. (NASDAQ:REPL) Director Fund Iv L.P. Omega sold 3,817 shares of the companys stock in a transaction that occurred on Monday, November 8th. The shares were sold at an average price of $33.53, for a total value of $127,984.01. The sale was disclosed in a document filed with the SEC, which is accessible []